Moomoo AI 已提取核心信息
On February 14, 2024, Ginkgo Bioworks Holdings, Inc. reported an amendment to the Schedule 13D filing by Jason Kelly, indicating a change in his ownership stake. The amendment, which is the third of its kind following previous filings, reflects a decrease in Kelly's percentage of Class A Common Stock ownership due to 'sell-to-cover' transactions to meet tax withholding obligations and sales under Rule 10b5-1 compliant plans. As of the amendment date, Kelly beneficially owns 85,752,333 shares, representing 5.0% of the company's Class A Common Stock, a reduction from his prior holdings. This includes both Class A and Class B shares, with the latter convertible to Class A on a one-to-one basis. The filing also marks an exit for Kelly as he ceases to be the beneficial owner of more than five percent of Ginkgo Bioworks' outstanding Class A shares. The transactions leading to this amendment occurred between December 20, 2023, and January 4, 2024, with sales executed through open market transactions at varying prices.
On February 14, 2024, Ginkgo Bioworks Holdings, Inc. reported an amendment to the Schedule 13D filing by Jason Kelly, indicating a change in his ownership stake. The amendment, which is the third of its kind following previous filings, reflects a decrease in Kelly's percentage of Class A Common Stock ownership due to 'sell-to-cover' transactions to meet tax withholding obligations and sales under Rule 10b5-1 compliant plans. As of the amendment date, Kelly beneficially owns 85,752,333 shares, representing 5.0% of the company's Class A Common Stock, a reduction from his prior holdings. This includes both Class A and Class B shares, with the latter convertible to Class A on a one-to-one basis. The filing also marks an exit for Kelly as he ceases to be the beneficial owner of more than five percent of Ginkgo Bioworks' outstanding Class A shares. The transactions leading to this amendment occurred between December 20, 2023, and January 4, 2024, with sales executed through open market transactions at varying prices.
2024年2月14日，Ginkgo Bioworks Holdings, Inc.报告了杰森·凯利对附表13D申报的修正案，表明其所有权发生了变化。该修正案是继先前申报之后的第三次此类修正案，反映了凯利在A类普通股所有权中所占百分比的下降，这是由于为履行预扣税义务和根据第10b5-1条的计划进行的销售而进行的 “卖出到封面” 的交易。截至修订日，凯利实益拥有85,752,333股股票，占公司A类普通股的5.0％，比他之前持有的有所减少。这包括A类和B类股票，后者可以一对一地转换为A类股票。该文件还标志着凯利退出，因为他不再是Ginkgo Bioworks已发行A类股票5％以上的受益所有人。导致该修正案的交易发生在2023年12月20日至2024年1月4日之间，通过公开市场交易以不同的价格进行销售。
2024年2月14日，Ginkgo Bioworks Holdings, Inc.报告了杰森·凯利对附表13D申报的修正案，表明其所有权发生了变化。该修正案是继先前申报之后的第三次此类修正案，反映了凯利在A类普通股所有权中所占百分比的下降，这是由于为履行预扣税义务和根据第10b5-1条的计划进行的销售而进行的 “卖出到封面” 的交易。截至修订日，凯利实益拥有85,752,333股股票，占公司A类普通股的5.0％，比他之前持有的有所减少。这包括A类和B类股票，后者可以一对一地转换为A类股票。该文件还标志着凯利退出，因为他不再是Ginkgo Bioworks已发行A类股票5％以上的受益所有人。导致该修正案的交易发生在2023年12月20日至2024年1月4日之间，通过公开市场交易以不同的价格进行销售。
有用
没用